TM

SCREEN OFTEN    ISOLATE EARLY    SLOW THE SPREAD

THE CDC AND WHO DESIGNATE

LOSS OF SMELL

AS A SYMPTOM OF COVID-19(1)

Three-Quarters of People with COVID-19 infection are Asymptomatic. (14) 

Optimist Screening was designed and clinically validated to detect anosmia (loss of smell), an early indicator of Covid-19 infection in Asymptomatic carriers. 

Asymptomatic Carriers or "Silent Spreaders" may experience no symptoms of infection other than loss of smell. (2)

Optimist Screening identifies approximately 73% of Covid-Positive

Asymptomatic persons by confirming loss of smell. (3)

Asymptomatic carriers are just as contagious as symptomatic carriers (4) and asymptomatics do not experience fever, so temperature scans are ineffective.

Acute loss of sense of smell needs to be considered globally as a criterion for self isolation, testing and contact tracing in order to contain the spread of COVID-19. (13)

Covid 19

80%

Up to

loss of smell

Up to 80% of people who test positive for Covid-19 complain of loss of smell. (2,5,6,7)

10X

Loss of smell

more

prevalent

For Covid-19 patients, loss of smell is 10 times more prevalent than fever or cough. (8)

or only sign

1st

Loss of smell can be the first or only sign of infection and usually precedes other common symptoms. (5)

100%

Silent

Spreaders

100% of Asymptomatic Carriers are infecting others without even realizing it. (7,9)

Incorporating Optimist Screening into your organization's safety protocol initiative shows your employees that their health and ensuring a safe work environment are top priorities.

Daily screening helps to identify loss of smell in Asymptomatic carriers within businesses, manufacturing plants, hospitals, schools, senior living facilities, restaurants,

churches, airports and public-event venues.

Slowing the spread protects productivity and revenue.

OPTIMIST SCREENING MAKES DETECTION OF ANOSMIA IN ASYMPTOMATIC CARRIERS SIMPLE AND EASILY SCALABLE

1
SPRAY
2
SMELL
3
CONFIRM

"Smells     like   mint."

Optimist Screening requires no medical training to administer and just seconds to produce results.

Optimist utilizes pharmaceutical-grade metered dose components and dry-spray technology to dispense precise volumes of commonly recognized odorants onto a disposable test sheet. The test subject smells the sheet, then confirms the particular scent. If the test subject cannot confirm the scent, this may indicate loss of smell from infection. Scanning our QR code links the subject to information about the nearest Covid-19 testing site.

THE ONLY CLINICALLY VALIDATED ANOSMIA TEST FOR SCREENING AND IDENTIFING ASYMPTOMATIC CARRIERS.

SIMPLE IMPLEMENTATION

No medical training required.

 

FAST AND EFFICIENT

About 5 seconds to administer

and results are immediate.

NON-INVASIVE

No throat or nose swabs.

 

CONTACT-LESS

No person-to-person contact.

METERED-DOSE PRECISION

Dispenses an exact amount of

odorant for consistent screening method.

 

DRY-SPRAY TECHNOLOGY

No wetting of test material.

PRESSURIZED CONTAINER

Does not draw particulates back into the device.

ROTATION OF ODORANTS

3 unique scents per kit, like orange, mint, and garlic to enable confirmation.

5

seconds

Optimist Screening takes only five seconds to complete and produces immediate results.

560

tests per kit

A large quantity of tests per kit makes Optimist Screening easily scalable.

All rights reserved. Copyright 2020, Optimist Screening LLC